The U.S. point of care lipid test market, valued at USD 312.04 million in 2024, is projected to grow at a robust CAGR of 5.9% from 2025 to 2034, reaching a market value of USD 553.25 million by 2034, according to the latest market analysis. The surge in demand for rapid, portable diagnostic testing and the rising prevalence of cardiovascular diseases are among the primary drivers of this market’s expansion.
Market Overview
Point of care (POC) lipid testing is transforming preventive healthcare by enabling immediate cholesterol and lipid profile assessments at non-laboratory settings such as clinics, pharmacies, or even at home. The key advantage lies in its ability to deliver real-time results, significantly reducing the turnaround time compared to traditional lab-based testing.
With cardiovascular diseases (CVDs) accounting for approximately one in every four deaths in the U.S., early detection and continuous monitoring of lipid levels have become essential components of disease management. Point of care lipid tests offer a convenient and cost-effective solution, helping clinicians and patients make informed treatment decisions rapidly. These tests are especially crucial in managing cholesterol screening, dyslipidemia, and lipid metabolism disorders, which are widely prevalent in the U.S. adult population.
Market Segmentation
The U.S. point of care lipid test market is segmented by product type, end user, and mode of delivery.
By Product Type
Total Cholesterol Test Kits
HDL Cholesterol Test Kits
LDL Cholesterol Test Kits
Triglycerides Test Kits
Multi-panel Lipid Test Kits
Among these, multi-panel lipid test kits hold the dominant share due to their ability to offer comprehensive lipid profiling in one step, improving diagnostic accuracy and reducing patient inconvenience.
By End User
Hospitals and Clinics
Ambulatory Surgical Centers
Homecare Settings
Pharmacies and Retail Clinics
Hospitals and clinics remain the largest segment, but homecare settings are witnessing rapid growth due to the increasing use of self-monitoring devices and the availability of telemedicine platforms that support remote diagnostics.
By Mode of Delivery
Device-Based Testing
Strip-Based Testing
Strip-based testing is widely used due to its portability, affordability, and ease of use, particularly in rural or resource-limited settings.
Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/us-point-of-care-lipid-test-market
Key Market Growth Drivers
Rising Burden of Cardiovascular Diseases: The high prevalence of hypercholesterolemia and obesity in the U.S. population has intensified the need for regular lipid testing. The American Heart Association recommends routine lipid screenings, which is driving test adoption.
Advancements in Diagnostic Technologies: Modern lipid testing devices offer accurate results in under 5 minutes. Newer devices are being integrated with smartphone applications, facilitating digital tracking and physician consultations.
Increased Demand for Home Diagnostics: The COVID-19 pandemic created a cultural shift toward home-based healthcare. Consumers now expect convenient, accurate health monitoring tools without needing to visit medical facilities.
Supportive Government Initiatives: The CDC’s National Cholesterol Education Program and various state-level heart health campaigns encourage early screening and proactive lipid management.
Market Challenges
Despite strong growth prospects, the market faces certain hurdles:
Reimbursement and Cost Barriers: Not all POC lipid tests are covered by health insurance providers, limiting access for lower-income groups.
Variability in Test Accuracy: While POC devices have improved, some may still lack the accuracy of lab-based results, especially in complex lipid disorders.
Regulatory and Compliance Concerns: Stringent FDA regulations and Clinical Laboratory Improvement Amendments (CLIA) certification requirements can slow the time-to-market for new entrants.
Regional Analysis
The U.S. point of care lipid test market demonstrates varied growth across regions, influenced by healthcare infrastructure, chronic disease prevalence, and technology adoption.
Northeast: Home to a concentration of academic hospitals and biotech innovators, this region leads in clinical implementation of POC diagnostics.
Midwest: With a growing aging population and significant incidence of heart disease, this area shows a high demand for cholesterol screening in community clinics.
South: This region has the highest rates of obesity and cardiovascular mortality, driving aggressive testing campaigns and adoption of rapid diagnostics.
West: Technologically progressive states like California are witnessing increased use of mobile and connected devices for personal health monitoring.
Key Companies Operating in the U.S. Market
The competitive landscape is shaped by a mix of global leaders and regional specialists. Companies are investing in digital connectivity, wearable health tech integration, and cloud-based result management systems to differentiate their offerings.
Abbott Laboratories – Known for its Cholestech LDX™ System, widely used in point-of-care cholesterol testing.
Callegari Srl – Offers innovative diagnostic kits focused on user-friendly design and speed.
F. Hoffmann-La Roche Ltd. – Develops portable lipid analyzers with strong clinical validation.
Menarini Group – Provides automated testing systems used in primary care environments.
MiCoBio – Specializes in compact, connected lipid testing systems.
Nova Biomedical – Manufactures StatStrip® and other devices for blood chemistry analysis.
SD Biosensor, Inc. – Rapidly expanding with its cost-effective diagnostic solutions.
Sinocare Inc. – Known for affordability and ease of use in community testing programs.
VivaChek Biotech (Hangzhou) Co., Ltd. – Focuses on high-accuracy, multi-analyte test devices.
Conclusion
The U.S. point of care lipid test market is on a strong upward trajectory, driven by a convergence of technological innovation, consumer demand for instant diagnostics, and urgent national health priorities related to cardiovascular diseases. As the healthcare ecosystem shifts toward preventive care, personalized treatment, and remote monitoring, the adoption of lipid POC tests will continue to surge.
However, for the market to realize its full potential, stakeholders must address affordability, accuracy, and regulatory challenges. Partnerships between device manufacturers, healthcare providers, and payers will be essential in broadening access to these life-saving tools.
With innovation continuing to disrupt the diagnostic landscape, the next decade is poised to redefine how Americans manage their heart health—one drop of blood at a time.
More Trending Latest Reports By Polaris Market Research:
AI Trust, Risk and Security Management Market
Hospital Electronic Health Records Market
Metal Li-based Battery Casing Market
Imidazoline Derivative Inhibitor Market
Hospital Electronic Health Records Market
Low Temperature Powder Coatings Market
